A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
Summary
The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo; and determine the levels of PF-04447943 in the plasma over the course of the study.
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Conditions
Alzheimer's Disease
Intervention
PF-04447943, Placebo
Location
Pfizer Investigational Site
Northport
Alabama
United States
35476
Status
Recruiting
Source
Pfizer
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00930059
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Neuropil Threads
Abnormal structures located chiefly in distal dendrites and, along with NEUROFIBRILLARY TANGLES and SENILE PLAQUES, constitute the three morphological hallmarks of ALZHEIMER DISEASE. Neuropil threads are made up of straight and paired helical filaments which consist of abnormally phosphorylated microtubule-associated tau proteins. It has been suggested that the threads have a major role in the cognitive impairment seen in Alzheimer disease.
Alzheimer Vaccines
Vaccines or candidate vaccines used to prevent or treat ALZHEIMER DISEASE.
Aphasia, Primary Progressive
A progressive form of dementia characterized by the global loss of language abilities and initial preservation of other cognitive functions. Fluent and nonfluent subtypes have been described. Eventually a pattern of global cognitive dysfunction, similar to ALZHEIMER DISEASE, emerges. Pathologically, there are no Alzheimer or PICK DISEASE like changes, however, spongiform changes of cortical layers II and III are present in the TEMPORAL LOBE and FRONTAL LOBE. (From Brain 1998 Jan;121(Pt 1):115-26)
Amyloid Beta-protein Precursor
A precursor to the AMYLOID BETA-PROTEIN (beta/A4). Alterations in the expression of the amyloid beta-protein precursor (ABPP) gene, located on chromosome 21, plays a role in the development of the neuropathology common to both ALZHEIMER DISEASE and DOWN SYNDROME. ABPP is associated with the extensive extracellular matrix secreted by neuronal cells. Upon cleavage, this precursor produces three proteins of varying amino acid lengths: 695, 751, and 770. The beta/A4 (695 amino acids) or beta-amyloid protein is the principal component of the extracellular amyloid in senile plaques found in ALZHEIMER DISEASE; DOWN SYNDROME and, to a limited extent, in normal aging.
Down Syndrome
A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe MENTAL RETARDATION. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
Clinical Trials
Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.
This study is designed to investigate the safety, tolerability, and pharmacokinetics of PF-04447943 after single and multiple-dose administration to healthy young adult and elderly Japanes...
A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers
To describe the safety, tolerability and pharmacokinetics of PF-04447943 after administration of multiple, ascending, oral doses to healthy elderly subjects.
Evaluate the safety and tolerability of PF-04447943 after administration of multiple doses in healthy elderly participants. Evaluate plasma drug levels and effects on cognition.
Alzheimer's Disease: Therapeutic Potential of Estrogen
This is a 15-month study to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with Alzheimer's di...
Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.
PubMed Articles
Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.
Background: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer's disease (AD). Methods:...
Clinical and biomarker changes in Alzheimer's disease.
To the Editor: In reporting the results of the Dominantly Inherited Alzheimer Network (DIAN) study, Bateman and colleagues (Aug. 30 issue)(1) describe clinical and biomarker changes in dominantly inhe...
Clinical and biomarker changes in Alzheimer's disease.
To the Editor: In reporting the results of the Dominantly Inherited Alzheimer Network (DIAN) study, Bateman and colleagues (Aug. 30 issue)(1) describe clinical and biomarker changes in dominantly inhe...
Clinical and biomarker changes in Alzheimer's disease.
To the Editor: In reporting the results of the Dominantly Inherited Alzheimer Network (DIAN) study, Bateman and colleagues (Aug. 30 issue)(1) describe clinical and biomarker changes in dominantly inhe...
Clinical and biomarker changes in Alzheimer's disease.
To the Editor: In reporting the results of the Dominantly Inherited Alzheimer Network (DIAN) study, Bateman and colleagues (Aug. 30 issue)(1) describe clinical and biomarker changes in dominantly inhe...